{"filings":[{"id":759757,"accession_number":"0001193125-26-249790","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2026-06-01T12:07:23+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Rallybio to merge with Avenzo Therapeutics; pre-merger Avenzo holders to own ~56.6% of combined co","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Avenzo stockholders expected to own ~56.6% of combined co; Rallybio stockholders ~2.8%; new investors in $215M concurrent financing ~40.6% on fully diluted basis.","Rallybio will distribute net cash to stockholders pre-closing; holders receive CVRs for potential proceeds from legacy asset sales.","Combined company led by Avenzo management: Dr. Athena Countouriotis as CEO, Scott Lipman as CFO; current Rallybio executives/directors expected to resign.","Merger requires Rallybio stockholder approval, reverse stock split, name change to Avenzo Therapeutics; closing conditions include $215M financing and no material adverse effect.","Support agreements from ~24.3% of Rallybio stockholders and ~78% of Avenzo stockholders; lock-up agreements for Avenzo insiders for 180 days post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95105,"accession_number":"0001193125-26-202601","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.02","1.01","9.01"],"status":"ready","headline":"Rallybio receives $50M termination fee after Candid merger terminates for UCB deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Candid Therapeutics terminated its merger with Rallybio to enter a Permitted Alternative Agreement with UCB S.A.","Rallybio entitled to $50,000,000 Parent Termination Fee plus $375,000 expense reimbursement, payable by May 4, 2026.","Rallybio, Candid and UCB entered a waiver releasing claims and waiving certain merger rights.","Rallybio intends to withdraw its Form S-4 registration statement filed for the merger.","The termination fee provides immediate cash, but the merger failure is a setback for Rallybio's strategic plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107940,"accession_number":"0001628280-26-022385","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rallybio CMO Steven Ryder departs immediately; severance tied to pending Candid merger","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Ryder, M.D., Chief Medical Officer, leaves Rallybio effective March 31, 2026.","Severance includes payments for without-cause termination; additional contingent on Candid merger close.","Equity awards remain outstanding and vest per Merger Agreement; exercisable 90 days post-close.","Pending business combination with Candid Therapeutics announced March 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107939,"accession_number":"0001193125-26-084444","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Rallybio agrees to reverse merger with Candid; Rallybio holders get ~3.65% of combined firm","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Rallybio pre-merger holders expected to own ~3.65% of combined company; Candid holders ~57.55%; financing investors ~38.80% (based on $505.5M raise).","Concurrent $505.5M private placement from accredited investors, shares convert to Rallybio common at closing.","Post-merger CEO will be Ken Song, current Candid Chairman/President/CEO; current Rallybio executives to resign.","Rallybio regained Nasdaq $1.00 bid compliance after 1-for-8 reverse stock split effective Feb 6, 2026.","Rallybio stockholders must approve share issuance (>20%), reverse split, name change to 'Candid Therapeutics, Inc.'"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107938,"accession_number":"0001739410-26-000010","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Rallybio announces 1-for-8 reverse stock split effective Feb 6, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split at 1-for-8 ratio approved by shareholders; effective 12:01 a.m. ET on Feb 6, 2026.","Shareholder vote: 34,507,021 for, 464,514 against, 11,939 abstain; no broker non-votes.","Post-split CUSIP changes to 75120L 209; trading symbol RLYB on Nasdaq remains unchanged.","Board selected 1-for-8 ratio from authorized range of 1-for-5 to 1-for-20 per shareholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124356,"accession_number":"0001739410-25-000131","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio posts Q3 net income of $16.0M on $20M REV102 sale; RLYB116 data expected Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.2M vs $0.3M YoY; R&D expenses fell to $4.1M (from $8.2M); G&A $3.0M (from $4.1M).","Net income $16.0M ($0.36/share) vs net loss $11.5M in Q3 2024; includes $20M from sale of REV102 interest.","Cash and securities $59.3M as of Sept 30; expected to fund operations through 2027.","Completed Cohort 1 dosing of RLYB116 confirmatory PK/PD study; data on track for Q4 2025.","RLYB332 development plans being evaluated; preclinical data show superior PD vs comparator molecules."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":636000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141026,"accession_number":"0001193125-25-192749","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Rallybio fails Nasdaq bid price compliance; transfer to Capital Market grants extension to Feb 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Rallybio on Aug 26, 2025 of transfer to Capital Market; stock continues trading as RLYB.","Company failed to regain $1.00 minimum bid price by Aug 25, 2025 deadline; new compliance date is Feb 23, 2026.","If not compliant by Feb 23, 2026, Nasdaq will issue delisting notice; Rallybio may appeal or pursue reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141025,"accession_number":"0001739410-25-000108","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q2 net loss $9.7M, sells REV102 to Recursion for $25M; RLYB116 data Q3/Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.7M ($0.22/share) vs $16.2M in Q2 2024; revenue $0.2M.","Sold REV102 to Recursion for up to $25M, including $7.5M upfront equity; cash runway extended into mid-2027.","RLYB116 confirmatory PK/PD study dosing started; Cohort 1 and Cohort 2 topline data expected Q3 and Q4 2025.","RLYB212 program discontinued after Phase 2 PK data missed target concentrations.","Cash, equivalents and marketable securities $45.7M at June 30, 2025; with REV102 payment, runway into mid-2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":424000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141024,"accession_number":"0001739410-25-000100","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"Rallybio sells ENPP1 JV stake to Recursion for up to $25M; cash runway to mid-2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront equity payment of $7.5M (1,457,952 Recursion shares); potential $12.5M contingent equity and $5M clinical milestone.","Rallybio eligible for low single-digit royalties on future net sales of REV102 (ENPP1 inhibitor for HPP).","Deal extends Rallybio's cash runway to mid-2027; company sharpens focus on RLYB116 confirmatory study topline data this year.","REV102 was in IND-enabling studies; Recursion gains full ownership to accelerate development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158803,"accession_number":"0001739410-25-000093","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rallybio enters into employment agreement with CMO Steven Ryder; base salary $531,227","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Base salary $531,227 per year; target annual bonus of up to 40% of base salary.","Initial one-year term auto-renewing annually unless 60-day non-extension notice given.","Severance on non-cause/good reason termination: 12 months base salary and COBRA premiums.","Change-in-control severance: 1.5x (base + target bonus) paid over 18 months plus full vesting of time-based equity.","Non-compete and non-solicit covenants apply during employment and for one year post-termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158802,"accession_number":"0001739410-25-000089","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rallybio shareholders elect Mackay and Soteropoulos as directors, ratify Deloitte as auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Martin W. Mackay elected as Class I director with 23,833,701 for and 3,132,991 against.","Paula Soteropoulos elected as Class I director with 23,812,816 for and 3,153,701 against.","Ratification of Deloitte & Touche as independent auditor for FY2025: 34,632,324 for, 40,810 against, 1,758 abstentions.","Broker non-votes totaled 7,708,200 on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158801,"accession_number":"0001739410-25-000059","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q1 net loss $9.4M; discontinues RLYB212, cuts workforce 40%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.4M ($0.21 per share) vs $19.0M ($0.47) in Q1 2024; revenue $0.2M from J&J collaboration.","Cash, cash equivalents, and marketable securities $54.5M; runway into 1H 2027.","RLYB212 program discontinued after Phase 2 PK data missed target concentrations.","Workforce reduction of 40% (nine positions) with ~$1.7M in severance charges; substantially complete by end of Q2 2025.","RLYB116 confirmatory PK/PD study on track to start in Q2 2025; Cohort 1 data in Q3, Cohort 2 in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":212000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158800,"accession_number":"0001739410-25-000052","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rallybio discontinues RLYB212 for FNAIT after Phase 2 PK misses efficacy targets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 PK results: RLYB212 concentrations near/ below assay LLoQ, missing minimum target of 3 ng/mL and predicted 6-10 ng/mL.","No further enrollment; safety follow-up of sentinel participant continues; dose adjustment not feasible.","RLYB116 confirmatory PK/PD study to initiate Q2 2025 with data from Cohorts 1 and 2 in 3Q/4Q 2025.","REV102 (ENPP1 inhibitor, JV with Recursion) in IND-enabling studies; Phase 1 expected 2026; preclinical data 2H 2025.","RLYB332 (long-acting matriptase-2 antibody) preclinical development ongoing for iron overload diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177207,"accession_number":"0001739410-25-000041","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rallybio reduces ATM offering cap from $100M to $9.55M under Sales Agreement with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment reduces aggregate offering price from $100,000,000 to $9,550,000.","As of March 13, 2025, no shares have been sold under the Sales Agreement.","TD Cowen receives up to 3.0% commission on gross proceeds in at-the-market sales.","Sales limited by public float rule: cannot exceed one-third of non-affiliate market value if public float <$75M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177206,"accession_number":"0001739410-25-000029","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q4 net loss $11M, cash $65.5M; key trial data readouts in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $11.0M ($0.25/share) vs $20.2M ($0.50/share) in Q4 2023; full-year loss $57.8M.","Revenue $38k in Q4 2024 from J&J collaboration; zero revenue in year ago period.","Cash, equivalents, and marketable securities $65.5M as of Dec 31, 2024; runway into 2H 2026.","RLYB212 Phase 2 sentinel participant dosed; PK/safety data from 2nd trimester expected Q2 2025, at delivery Q3 2025.","RLYB116 confirmatory PK/PD study to start Q2 2025; Cohorts 1 and 2 data in Q3/Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177205,"accession_number":"0001739410-25-000021","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Rallybio receives Nasdaq bid price deficiency notice; faces potential delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice on Feb 24, 2025: closing bid price below $1.00 for 30 consecutive business days.","Company has 180 days, until August 25, 2025, to regain compliance by closing at $1.00+ for 10 days.","If not cured, may qualify for additional 180-day period by transferring to Nasdaq Capital Market.","Failure to regain compliance could lead to delisting and potential appeal to Nasdaq Hearings Panel.","No immediate impact on trading; stock continues to list on Nasdaq under other requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193978,"accession_number":"0001739410-24-000132","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q3 net loss narrows to $11.5M; RLYB212 Phase 2 to screen in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.5M ($0.26/share) vs $18.4M ($0.45) in Q3 2023; revenue $0.3M from J&J collaboration.","Cash $75.1M as of Sep 30, 2024 provides runway into mid-2026; R&D expenses down 38% to $8.2M.","RLYB212 Phase 2 CTA approved by EMA and MHRA; screening for pregnant women at FNAIT risk to start Q4 2024.","RLYB116 manufacturing improvements completed; biomarker data suggests potential in PNH and APS beyond myasthenia gravis.","ENPP1 inhibitor candidate nomination with Exscientia on track for Dec 2024; preclinical data showed PPi reduction and improved bone mineralization."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":598000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210308,"accession_number":"0001739410-24-000121","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Kush Parmar to resign from Rallybio Board effective Oct 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kush Parmar resigns from the Board and as Chair of the Nominating and Corporate Governance Committee.","Resignation effective October 31, 2024; not due to any dispute or disagreement with Rallybio.","No replacement for Parmar's Board seat announced as of filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210307,"accession_number":"0001739410-24-000114","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q2 net loss $16.2M; cash $88.6M; RLYB212 Phase 2 on track for Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $16.2M ($0.37/share) vs $18.6M ($0.46/share) in Q2 2023.","Revenue $0.3M from J&J collaboration; no revenue in prior year.","Cash, equivalents, and securities $88.6M as of June 30, expecting runway into mid-2026.","RLYB212 Phase 2 trial in pregnant women at risk of FNAIT remains on track to start Q4 2024.","Epidemiological analysis estimates >30,000 higher-risk pregnancies/year in North America and major European countries, 40% above prior estimates."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":299000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210306,"accession_number":"0001739410-24-000105","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rallybio Executive Chairman Martin Mackay to resign employment, stay as Chairman and consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martin Mackay will resign as Executive Chairman and employee effective Dec 31, 2024; no severance paid.","He will remain as Chairman of the Board; consulting agreement from Jan 1, 2025 to Jan 1, 2026 at $18,750/month.","Outstanding unvested time-based equity awards will vest immediately upon a Change of Control during consultancy.","Dr. Mackay eligible for 2024 annual bonus based on performance, paid at same time as employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228617,"accession_number":"0001739410-24-000098","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rallybio shareholders elect four Class III directors and ratify Deloitte as auditor.","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Wendy K. Chung, Robert Hopfner, Ronald Hunt, and Hui Liu as Class III directors for terms expiring in 2027.","Broker non-votes totaled 4,647,512 on director elections, reflecting significant retail holder participation.","Ratified Deloitte & Touche as independent auditor for FY 2024 with 31,396,236 for, 32,355 against, and 7,173 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228616,"accession_number":"0001739410-24-000053","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio posts Q1 net loss of $19.0M; cash $94.2M; on track for RLYB212 Phase 2 in 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.0M ($0.47 per share) vs $17.3M ($0.43 per share) in Q1 2023.","Cash, cash equivalents, and marketable securities of $94.2M as of March 31, 2024; runway into mid-2026.","Announced 45% workforce reduction in Feb 2024 to focus on RLYB212 and RLYB116.","Collaboration with Johnson & Johnson (Momenta) for FNAIT; received $6.6M equity investment.","Phase 2 trial of RLYB212 in pregnant women at risk for FNAIT on track for 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228615,"accession_number":"0001739410-24-000040","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Rallybio announces J&J collaboration with $0.5M upfront and $6.6M equity for FNAIT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration with J&J: Rallybio receives $0.5M upfront, up to $3.7M milestones for FNAIT data sharing and awareness.","J&J affiliate JJDC invests $6.6M via purchase of 3.6M shares in private placement at ~$1.82/share.","Rallybio's RLYB212 (preventative for non-alloimmunized) and J&J's nipocalimab (for alloimmunized) target FNAIT; Phase 2 for RLYB212 expected H2 2024.","JJDC locked up from selling shares for 180 days; collaboration agreement expires April 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247263,"accession_number":"0001739410-24-000030","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio reports Q4 net loss $20.2M, cash $109.9M; workforce cut 45%, Phase 2 RLYB212 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $20.2M ($0.50/sh); full year loss $74.6M ($1.84/sh).","Cash, equivalents, marketable securities $109.9M at Dec 31, 2023; runway into mid-2026 after 45% workforce reduction.","EMA protocol assistance feedback received for RLYB212; Phase 2 FNAIT study expected to start 2H 2024.","RLYB116 Phase 1 multiple dose showed >93% free C5 reduction; manufacturing enhancements to enable higher doses.","R&D expenses $53.5M (up 31% YoY); G&A $25.4M (down 7% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247262,"accession_number":"0001739410-24-000012","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Rallybio cuts 45% of workforce, extends cash runway to mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 45% (19 positions); expects ~$3.3M in severance charges.","Preliminary cash, equivalents and marketable securities of $109.9M as of Dec 31, 2023.","Prioritizes Phase 2-ready programs RLYB212 (FNAIT) and RLYB116 (C5 inhibitor).","Cash runway extended into mid-2026; preclinical programs seek alternative funding.","RLYB212 Phase 2 update with EMA expected H1 2024; Phase 2 initiation in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264692,"accession_number":"0001739410-23-000019","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rallybio reveals Phase 1 MAD data for RLYB116: >93% free C5 reduction at 100 mg weekly; cash runway extended to 3Q 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100 mg weekly dose of RLYB116 achieved >93% mean reduction in free C5 at Day 29; >99% reduction 24h post-first dose.","RLYB116 half-life >300 hours; low inter-subject variability; all adverse events mild, most common injection-site reaction (60% in 100mg cohort).","Company deprioritizes Phase 2 start in gMG, focusing on manufacturing to improve tolerability and widen indications.","Cash runway guidance updated: current resources expected to fund operations into Q3 2025.","RLYB212 for FNAIT continues as lead program; near-term RLYB116 investments directed to process improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264691,"accession_number":"0001739410-23-000011","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio reports Q3 2023 net loss of $18.4M ($0.45/share); cash $121.4M, runway into Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.4M, or $0.45 per share, unchanged from Q3 2022 net loss of $18.4M ($0.60 per share).","R&D expenses $13.3M (up vs $12.1M in Q3 2022) on advancing RLYB212 and RLYB331; G&A expenses $6.1M (down from $6.8M).","Cash, cash equivalents and marketable securities $121.4M as of Sept 30, 2023; expected to fund operations into Q1 2025.","On track for 4Q 2023 data readouts: RLYB212 Phase 1 multiple dose cohort initial data and RLYB116 Phase 1 MAD data including safety, PK, PD.","RLYB212 Phase 2 dose confirmation study in pregnant women expected to initiate in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281927,"accession_number":"0001739410-23-000004","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q2 net loss $18.6M; cash $137.8M; CEO transition to Stephen Uden","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.6M ($0.46/sh) vs $17.6M ($0.57/sh) in Q2 2022; R&D expense $13.1M, up from $10.1M.","Cash, equivalents and marketable securities $137.8M as of June 30, providing runway into 1Q 2025.","RLYB212 Phase 1b proof-of-concept met endpoint; multiple-dose cohort data and tox results expected in 4Q 2023.","RLYB116 Phase 1 MAD study initial data (safety, PK, PD) and indication strategy expected in 4Q 2023.","Effective Aug 1, Stephen Uden became CEO; Martin Mackay appointed Executive Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300929,"accession_number":"0000950170-23-030535","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rallybio appoints Stephen Uden as CEO effective Aug 1; Martin Mackay becomes Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Uden, current President and COO, named CEO effective Aug 1, 2023; will also join the Board.","Co-founder Martin Mackay transitions from CEO to Executive Chairman, remains full-time employee focusing on strategy and IR.","Phase 1 multiple dose cohort data for RLYB212 and initial data for RLYB116 expected in Q4 2023.","Board size increased to 11 directors; Uden appointed as Class II director with term through 2026 annual meeting.","Uden's base salary stays at $530,000, target bonus 45%; Mackay's compensation unchanged; severance terms similar."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300928,"accession_number":"0000950170-23-023468","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rallybio shareholders elect three Class II directors and ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Helen Boudreau, Lucian Iancovici, and Christine Nash elected as Class II directors for terms expiring 2025.","Vote totals: Boudreau 18,762,070 for, 6,047,659 against; Iancovici 18,875,144 for, 5,934,499 against; Nash 18,763,528 for, 6,046,201 against.","Appointment of Deloitte & Touche as independent auditor for FY2023 ratified with 27,911,030 for, 4,866 against, 230 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300927,"accession_number":"0000950170-23-019161","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q1 net loss $17.3M; cash $150.4M; RLYB212 data expected Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.3M ($0.43 per share) vs $14.5M ($0.48) in Q1 2022.","Cash, cash equivalents and marketable securities $150.4M as of March 31, 2023; runway into Q1 2025.","RLYB212 multiple dose cohort initiated; Phase 1b data to be presented at ISTH June 2023; cohort data expected Q4 2023.","RLYB116 multiple ascending dose study ongoing; initial safety, PK and PD data expected Q4 2023.","Research collaboration with EyePoint announced for sustained intraocular delivery of C5 inhibitor targeting geographic atrophy."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320817,"accession_number":"0000950170-23-006125","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Rallybio reports FY2022 net loss of $66.7M; RLYB212 achieves proof-of-concept in Phase 1b","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss for FY2022 was $66.7M ($2.09/share) vs $47.0M ($1.84/share) in 2021; Q4 loss $16.2M.","RLYB212 Phase 1b proof-of-concept: single dose eliminated >90% of HPA-1a positive platelets; well-tolerated.","Cash, equivalents, and marketable securities $169.0M as of Dec 31, 2022; runway into Q1 2025.","RLYB211 discontinued; RLYB212 multi-dose cohort initiated, data expected Q4 2023.","Jonathan Lieber appointed CFO effective Feb 1, 2023; follow-on offering raised ~$55M in Nov 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320816,"accession_number":"0000950170-23-001474","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rallybio appoints Jonathan Lieber as CFO; co-founder Fryer departs Feb 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jonathan Lieber appointed CFO effective Feb 1, 2023; most recently CFO of AGTC.","Base salary $460K, sign-on bonus $100K, target bonus up to 40% of base.","Grant of option to purchase 240,000 shares, vesting over 4 years.","Co-founder and former CFO Jeffrey Fryer departs Feb 15 after transition period.","Lieber brings 30+ years experience as CFO and investment banker; also on board of Salarius Pharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338951,"accession_number":"0001193125-22-295957","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Underwriters partially exercise overallotment option, purchasing 803,654 shares at $6.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters purchased 803,654 additional shares at $6.00 per share, less discounts and commissions.","Exercise is partial exercise of underwriters' 30-day option from November 10, 2022 underwriting agreement.","Closing expected on or about December 1, 2022, subject to customary conditions.","Previously announced offering included 5,000,001 shares and pre-funded warrants for up to 3,333,388 shares.","Offering made under effective shelf registration statement (File No. 333-266668)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338950,"accession_number":"0001193125-22-284569","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Rallybio announces underwritten public offering of 5,000,001 shares at $6.00/share plus pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,000,001 shares of common stock at $6.00 per share and pre-funded warrants for 3,333,388 shares at $5.9999 each.","Underwriters granted 30-day option to purchase up to an additional 1,250,000 shares.","Pre-funded warrants have $0.0001 exercise price, are exercisable immediately, and do not expire.","Closing expected on or about November 15, 2022, subject to customary conditions.","J.P. Morgan, Cowen, and Evercore are joint book-running managers for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338949,"accession_number":"0000950170-22-022335","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q3 net loss widens to $18.4M; positive RLYB116 Phase 1 data with >99% C5 reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.4M for Q3 2022, vs $10.2M for Q3 2021; net loss per share $0.60.","Cash, cash equivalents, and marketable securities $132.4M as of Sep 30, 2022; runway into Q1 2024.","RLYB212 Phase 1b shows rapid elimination of transfused platelets; proof-of-concept data expected Q1 2023.","RLYB116 Phase 1: >99% reduction in free C5 within 24 hrs at 100 mg SC; half-life >300 hrs; MAD study in Q1 2023.","R&D expenses $12.1M (up 142% YoY) driven by RLYB212 and RLYB116 development."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356327,"accession_number":"0000950170-22-018936","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2022-09-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rallybio: RLYB212 Phase 1b rapidly eliminates HPA-1a platelets; proof-of-concept data Q1 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RLYB212 showed >90% reduction in mean platelet elimination half-life vs placebo in Phase 1b.","Single subcutaneous dose eliminated transfused HPA-1a positive platelets rapidly one week after dosing.","No serious adverse events; safety and tolerability acceptable.","Protocol amended to increase dose and expand PK/PD sampling; registrational trial dosing expected to be informed.","Proof-of-concept data from Phase 1b study expected in Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356326,"accession_number":"0000950170-22-015259","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q2 net loss $17.6M; Phase 1b RLYB212 shows platelet elimination; CFO to retire","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.6M ($0.57/share) vs $11.1M ($0.49) in Q2 2021 on higher R&D and G&A expenses.","Cash, equivalents and securities $147.4M as of June 30, 2022; runway into Q1 2024.","Phase 1b RLYB212 shows rapid elimination of HPA-1a positive platelets; protocol amended for broader dose range.","Phase 1 RLYB116 on track; initial single-dose data for 30 mg expected Q4 2022.","CFO Jeffrey Fryer to retire; external search for successor begun."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356325,"accession_number":"0000950170-22-013744","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Rallybio appoints Wendy K. Chung, M.D., Ph.D., to its Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 9 to 10; Dr. Chung fills newly created vacancy effective Aug 1, 2022.","Dr. Chung appointed as Class III director with term expiring at 2024 annual meeting.","She will serve on the Nominating and Corporate Governance Committee.","Compensation follows standard non-employee director policy; no material transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374717,"accession_number":"0000950170-22-011050","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rallybio CFO Jeff Fryer to retire; external search for successor initiated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Co-founder and CFO Jeff Fryer will retire; he will stay until a replacement is appointed.","External search for new CFO has been launched; transition period not yet specified.","Fryer expects to enter a confidential separation agreement upon his departure.","CEO Martin Mackay thanked Fryer for his role in building the company over four years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374716,"accession_number":"0000950170-22-010851","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rallybio annual meeting elects three Class I directors, ratifies Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Martin W. Mackay elected with 16,028,966 votes for, 297,302 withheld, 1,720,648 broker non-votes.","Kush M. Parmar elected with 15,217,584 for, 1,108,684 withheld, 1,720,648 broker non-votes.","Paula Soteropoulos elected with 16,037,821 for, 288,447 withheld, 1,720,648 broker non-votes.","Deloitte & Touche ratified as independent auditor for FY2022 with 18,045,373 for, 1,035 against, 508 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374715,"accession_number":"0000950170-22-008944","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Rallybio in-licenses RLYB331 from Sanofi; Q1 net loss $14.5M, cash $161.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide license from Sanofi for preclinical anti-MTP-2 antibody RLYB331; upfront $3M, up to $43M development & $150M commercial milestones.","Q1 2022 net loss of $14.5M ($0.48 per share) vs. $13.3M ($0.60) in Q1 2021; R&D spend $7.6M, G&A $6.7M.","Cash, equivalents & marketable securities $161.4M as of March 31, 2022.","Phase 1b proof-of-concept study for RLYB212 (FNAIT) initiated; initial data expected in Q3 2022.","Phase 1 study of RLYB116 (complement inhibitor) ongoing; single-dose data expected in H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374714,"accession_number":"0000950170-22-005307","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2022-04-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Rallybio appoints Christine Nash and Hui Liu to board; Shannon to resign at annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 8 to 10; Christine Nash and Hui Liu appointed as directors effective April 4, 2022.","Nash appointed to Compensation Committee; Liu appointed to Audit Committee.","Director Timothy Shannon to resign at Rallybio's 2022 annual meeting of shareholders.","Nash brings rare disease commercial/product launch experience; Liu brings business development and finance expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393174,"accession_number":"0000950170-22-003666","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio reports Q4 2021 net loss of $12.4M; cash $175.3M; pipeline updates on RLYB212 and RLYB116","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.4M ($0.42 per share) for Q4 2021; full year net loss $47.0M ($1.84 per share).","Cash and cash equivalents of $175.3M as of December 31, 2021.","R&D expenses $6.1M in Q4 2021 ($26.9M FY); G&A $6.2M Q4 ($18.7M FY).","Phase 1b proof-of-concept for RLYB212 (FNAIT) to start Q2 2022; initial data expected Q3 2022.","Phase 1 study of RLYB116 (C5 inhibitor) initiated; single dose safety/PK/PD data expected 2H 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393173,"accession_number":"0000950170-22-002960","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2022-03-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rallybio doses first healthy volunteers in Phase 1 study of RLYB116; data expected H2 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First healthy volunteers dosed in Phase 1 study of RLYB116.","Single dose safety, PK, and PD data expected in second half of 2022.","Corporate presentation updated to reflect Phase 1 milestone and data timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411650,"accession_number":"0000950170-21-003919","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q3 net loss $10.2M ($0.37/share); cash $187M; pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.2M vs $7.2M in Q3 2020; R&D $5.0M flat; G&A $5.0M up from $1.6M.","Cash and equivalents $187.0M, including $83M net from August 2021 IPO.","Initiated FNAIT natural history study to support RLYB212 registration trial design.","On-track to report additional Phase 1/2 RLYB211 data in Q4 2021.","Phase 1 studies for RLYB212 and RLYB116 expected to start in Q1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430407,"accession_number":"0000950170-21-001739","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2021-09-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio reports Q2 net loss $11.1M; IPO gross proceeds $92.7M; pipeline on track for Phase 1 starts in Q1 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.1M ($2.80 per common unit) for Q2 2021, vs $4.9M in Q2 2020.","Cash and investments $112.7M as of June 30; August IPO added ~$83.2M net proceeds.","R&D expenses $6.8M in Q2 2021, up from $3.1M YoY, driven by RLYB212 and RLYB116 development.","Phase 1/2 data for RLYB211 (FNAIT) presented at ISTH; additional data expected Q4 2021.","Phase 1 studies of RLYB212 and RLYB116 planned to initiate in Q1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430406,"accession_number":"0001193125-21-233263","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2021-08-02T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"Rallybio completes IPO, files amended charter and bylaws on August 2, 2021","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized 200M shares of common stock and 50M shares of preferred stock in restated certificate.","Adopted amended and restated bylaws effective upon IPO closing, updating stockholder proposal procedures and director nomination rules.","Entered Registration Rights Agreement with stockholders on July 28, 2021 granting customary registration rights.","Registration Rights Agreement requires company to pay expenses of registrations, holders pay underwriting discounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}